83 related articles for article (PubMed ID: 35232282)
1. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
3. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers.
Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S
J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
5. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
[TBL] [Abstract][Full Text] [Related]
6. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
7. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract][Full Text] [Related]
8. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
Mallardo D; Sparano F; Vitale MG; Trojaniello C; Fordellone M; Cioli E; Esposito A; Festino L; Mallardo M; Vanella V; Facchini BA; De Filippi R; Meinardi P; Ottaviano M; Caracò C; Simeone E; Ascierto PA
Cancer Immunol Immunother; 2024 Jun; 73(8):160. PubMed ID: 38850335
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
[TBL] [Abstract][Full Text] [Related]
10. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab-Induced Hyperosmolar Hyperglycemic State With Concurrent Diabetic Ketoacidosis in a Patient Receiving Treatment for Cutaneous Squamous Cell Carcinoma.
Pyronneau A; Noronha K; Zucker A; Kennett R; Desai P
Cureus; 2024 May; 16(5):e60565. PubMed ID: 38764707
[TBL] [Abstract][Full Text] [Related]
12. The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.
Lo Greco MC; Marano G; Milazzotto R; Liardo RLE; Finocchiaro I; La Rocca M; Basile A; Foti PV; Palmucci S; David E; Pergolizzi S; Spatola C
J Pers Med; 2024 May; 14(6):. PubMed ID: 38929802
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation.
Potestio L; Scalvenzi M; Lallas A; Martora F; Guerriero L; Fornaro L; Marano L; Villani A
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730683
[TBL] [Abstract][Full Text] [Related]
14. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: a retrospective analysis.
Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885840
[TBL] [Abstract][Full Text] [Related]
15. Unresectable auricular squamous cell carcinoma with locoregional metastasis: use of cemiplimab in an immunosuppressed patient.
França TF; Gontijo JRV; Junior EFV; Lima EM
An Bras Dermatol; 2024; 99(1):158-160. PubMed ID: 37652819
[No Abstract] [Full Text] [Related]
16. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
Queirolo P; Cinquini M; Argenziano G; Bassetto F; Bossi P; Boutros A; Clemente C; de Giorgi V; Del Vecchio M; Patuzzo R; Pennachioli E; Peris K; Quaglino P; Reali A; Zalaudek I; Spagnolo F
ESMO Open; 2024 May; 9(5):103005. PubMed ID: 38688192
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh.
Dhillon J; Li DQ; Burnier M; Shenouda G; Arthurs BP; El-Hadad C
Orbit; 2024 Apr; 43(2):258-264. PubMed ID: 36052515
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report.
Alloghbi A; Ninia J; Alshare B; Hotaling J; Raza S; Sukari A
Clin Case Rep; 2021 Dec; 9(12):e05228. PubMed ID: 34950481
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors.
Likhitsup A; Fontana RJ
Curr Opin Gastroenterol; 2024 May; 40(3):164-171. PubMed ID: 38375823
[TBL] [Abstract][Full Text] [Related]
20. Extra-Anogenital Giant Cutaneous Squamous Cell Carcinomas.
Mateuszczyk MK; Chlebicka I; Łyko M; Maj J; Szepietowski JC
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]